 Amy Scurlock
Concepts (280)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 16 | 2024 | 98 | 4.520 |
Why?
| | Desensitization, Immunologic | 29 | 2025 | 107 | 4.000 |
Why?
| | Allergens | 27 | 2025 | 138 | 3.550 |
Why?
| | Peanut Hypersensitivity | 22 | 2025 | 88 | 3.470 |
Why?
| | Food Supply | 4 | 2024 | 90 | 1.350 |
Why?
| | Hypersensitivity | 4 | 2023 | 75 | 1.060 |
Why?
| | Chlamydia Infections | 8 | 2018 | 75 | 0.970 |
Why?
| | Administration, Oral | 24 | 2024 | 434 | 0.920 |
Why?
| | Egg Hypersensitivity | 7 | 2021 | 26 | 0.920 |
Why?
| | Antigens, Plant | 3 | 2020 | 15 | 0.830 |
Why?
| | Child | 38 | 2025 | 6910 | 0.790 |
Why?
| | Immunoglobulin E | 14 | 2021 | 91 | 0.740 |
Why?
| | Anaphylaxis | 5 | 2021 | 69 | 0.710 |
Why?
| | Gastrointestinal Tract | 3 | 2011 | 103 | 0.700 |
Why?
| | Immunotherapy | 2 | 2020 | 235 | 0.700 |
Why?
| | Allergy and Immunology | 2 | 2018 | 19 | 0.690 |
Why?
| | Immune Tolerance | 7 | 2022 | 84 | 0.630 |
Why?
| | Child, Preschool | 29 | 2025 | 3944 | 0.620 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2018 | 8 | 0.620 |
Why?
| | Age Factors | 1 | 2020 | 1110 | 0.560 |
Why?
| | Immunity, Mucosal | 3 | 2010 | 14 | 0.520 |
Why?
| | Humans | 59 | 2025 | 50509 | 0.510 |
Why?
| | Chlamydia muridarum | 5 | 2018 | 40 | 0.490 |
Why?
| | Interleukin-17 | 2 | 2013 | 37 | 0.460 |
Why?
| | Adolescent | 22 | 2024 | 6447 | 0.410 |
Why?
| | Uterine Cervicitis | 2 | 2013 | 3 | 0.410 |
Why?
| | Th1 Cells | 2 | 2010 | 53 | 0.370 |
Why?
| | Guideline Adherence | 2 | 2013 | 136 | 0.360 |
Why?
| | Neutrophil Infiltration | 1 | 2010 | 25 | 0.360 |
Why?
| | Th17 Cells | 1 | 2010 | 25 | 0.360 |
Why?
| | Immunoglobulin G | 5 | 2020 | 187 | 0.330 |
Why?
| | Female | 34 | 2025 | 27086 | 0.320 |
Why?
| | Eosinophilic Esophagitis | 2 | 2021 | 38 | 0.320 |
Why?
| | Mouth | 1 | 2009 | 32 | 0.310 |
Why?
| | Adult | 10 | 2024 | 13583 | 0.310 |
Why?
| | Basophils | 5 | 2015 | 15 | 0.300 |
Why?
| | Skin Tests | 6 | 2022 | 55 | 0.300 |
Why?
| | Macrophages | 1 | 2010 | 364 | 0.290 |
Why?
| | Primary Health Care | 1 | 2011 | 366 | 0.290 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2021 | 19 | 0.280 |
Why?
| | Emergency Service, Hospital | 1 | 2011 | 484 | 0.280 |
Why?
| | Prognosis | 6 | 2021 | 1978 | 0.280 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 462 | 0.270 |
Why?
| | Double-Blind Method | 8 | 2025 | 708 | 0.260 |
Why?
| | Reproductive Tract Infections | 2 | 2018 | 14 | 0.260 |
Why?
| | Male | 26 | 2025 | 25910 | 0.250 |
Why?
| | Anti-Allergic Agents | 2 | 2024 | 16 | 0.240 |
Why?
| | Young Adult | 8 | 2024 | 4106 | 0.240 |
Why?
| | Fear | 1 | 2006 | 84 | 0.240 |
Why?
| | Life Style | 1 | 2006 | 144 | 0.240 |
Why?
| | Food | 2 | 2018 | 66 | 0.240 |
Why?
| | Infant | 15 | 2024 | 3630 | 0.240 |
Why?
| | Follow-Up Studies | 5 | 2021 | 2241 | 0.220 |
Why?
| | Delphi Technique | 1 | 2024 | 55 | 0.220 |
Why?
| | Flow Cytometry | 3 | 2018 | 474 | 0.220 |
Why?
| | Informed Consent | 1 | 2024 | 97 | 0.210 |
Why?
| | 2S Albumins, Plant | 2 | 2020 | 7 | 0.210 |
Why?
| | Consensus | 1 | 2024 | 160 | 0.210 |
Why?
| | Candy | 1 | 2002 | 3 | 0.210 |
Why?
| | Nutritional Status | 1 | 2023 | 136 | 0.210 |
Why?
| | Pelvic Inflammatory Disease | 2 | 2013 | 8 | 0.200 |
Why?
| | Treatment Outcome | 11 | 2025 | 5285 | 0.190 |
Why?
| | Plasmids | 3 | 2018 | 164 | 0.190 |
Why?
| | Animals | 9 | 2018 | 13124 | 0.190 |
Why?
| | Toll-Like Receptor 8 | 1 | 2021 | 3 | 0.190 |
Why?
| | T-Lymphocytes | 3 | 2021 | 325 | 0.190 |
Why?
| | Enteritis | 1 | 2021 | 19 | 0.180 |
Why?
| | Mosaicism | 1 | 2021 | 18 | 0.180 |
Why?
| | Gastritis | 1 | 2021 | 32 | 0.180 |
Why?
| | B-Lymphocytes | 2 | 2021 | 171 | 0.180 |
Why?
| | Health Promotion | 1 | 2023 | 258 | 0.180 |
Why?
| | Pancytopenia | 1 | 2021 | 37 | 0.180 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 52 | 0.180 |
Why?
| | Chlamydia trachomatis | 2 | 2011 | 29 | 0.170 |
Why?
| | Quality of Life | 2 | 2022 | 852 | 0.160 |
Why?
| | Pollen | 1 | 2018 | 1 | 0.160 |
Why?
| | Interferon-gamma | 2 | 2018 | 177 | 0.160 |
Why?
| | Wiskott-Aldrich Syndrome Protein | 1 | 2018 | 2 | 0.150 |
Why?
| | Wiskott-Aldrich Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 158 | 0.150 |
Why?
| | United States | 4 | 2022 | 4958 | 0.150 |
Why?
| | Anti-Bacterial Agents | 3 | 2013 | 743 | 0.140 |
Why?
| | Administration, Sublingual | 3 | 2013 | 17 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2018 | 149 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2018 | 92 | 0.140 |
Why?
| | Eosinophils | 1 | 2017 | 40 | 0.140 |
Why?
| | Health Literacy | 1 | 2019 | 129 | 0.140 |
Why?
| | Immunologic Factors | 3 | 2022 | 111 | 0.140 |
Why?
| | Inflammation | 1 | 2021 | 610 | 0.140 |
Why?
| | Esophagus | 1 | 2017 | 83 | 0.130 |
Why?
| | Basophil Degranulation Test | 1 | 2015 | 3 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 572 | 0.120 |
Why?
| | Oviducts | 2 | 2013 | 8 | 0.120 |
Why?
| | Diagnostic Errors | 2 | 2013 | 66 | 0.120 |
Why?
| | Cytokines | 3 | 2021 | 606 | 0.120 |
Why?
| | Interleukin-23 | 1 | 2013 | 9 | 0.110 |
Why?
| | Meningitis, Pneumococcal | 1 | 2013 | 7 | 0.110 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 11 | 0.110 |
Why?
| | Egg Proteins | 2 | 2019 | 18 | 0.110 |
Why?
| | Interleukins | 1 | 2013 | 31 | 0.110 |
Why?
| | Toll-Like Receptor 2 | 2 | 2011 | 24 | 0.110 |
Why?
| | Patient Selection | 1 | 2015 | 259 | 0.110 |
Why?
| | Mycobacterium fortuitum | 1 | 2013 | 6 | 0.110 |
Why?
| | Manikins | 1 | 2013 | 35 | 0.110 |
Why?
| | Macrolides | 1 | 2013 | 16 | 0.110 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 1808 | 0.110 |
Why?
| | Mass Screening | 2 | 2018 | 344 | 0.110 |
Why?
| | Emergency Medicine | 1 | 2013 | 52 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 65 | 0.100 |
Why?
| | Clarithromycin | 1 | 2013 | 38 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 37 | 0.100 |
Why?
| | Arkansas | 5 | 2019 | 1984 | 0.100 |
Why?
| | HLA Antigens | 1 | 2012 | 52 | 0.100 |
Why?
| | Clindamycin | 1 | 2012 | 13 | 0.100 |
Why?
| | Methicillin | 1 | 2012 | 11 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2009 | 82 | 0.100 |
Why?
| | Mice, Knockout | 2 | 2013 | 844 | 0.100 |
Why?
| | Dermatitis, Atopic | 1 | 2012 | 34 | 0.100 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 72 | 0.100 |
Why?
| | Gonorrhea | 1 | 2011 | 9 | 0.100 |
Why?
| | Mice | 5 | 2018 | 5687 | 0.090 |
Why?
| | Medication Errors | 1 | 2011 | 25 | 0.090 |
Why?
| | Influenza Vaccines | 1 | 2011 | 31 | 0.090 |
Why?
| | Membrane Proteins | 2 | 2013 | 332 | 0.090 |
Why?
| | Epinephrine | 3 | 2019 | 97 | 0.090 |
Why?
| | Medicine, Chinese Traditional | 1 | 2010 | 6 | 0.090 |
Why?
| | Adaptive Immunity | 1 | 2011 | 32 | 0.090 |
Why?
| | Eye Infections, Bacterial | 1 | 2011 | 29 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2010 | 39 | 0.090 |
Why?
| | Anemia, Hemolytic | 1 | 2010 | 10 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2010 | 42 | 0.090 |
Why?
| | Influenza, Human | 1 | 2011 | 86 | 0.090 |
Why?
| | Pediatrics | 1 | 2013 | 283 | 0.090 |
Why?
| | Clinical Protocols | 1 | 2010 | 110 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2013 | 6263 | 0.080 |
Why?
| | Neutrophils | 1 | 2011 | 145 | 0.080 |
Why?
| | Antigenic Variation | 1 | 2009 | 3 | 0.080 |
Why?
| | Antibodies, Bacterial | 1 | 2009 | 27 | 0.080 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 188 | 0.080 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 265 | 0.080 |
Why?
| | Risk Factors | 4 | 2019 | 3724 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2012 | 321 | 0.080 |
Why?
| | Immunization | 2 | 2019 | 62 | 0.080 |
Why?
| | Cystic Fibrosis | 1 | 2010 | 147 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 486 | 0.070 |
Why?
| | Signal Transduction | 2 | 2012 | 1624 | 0.070 |
Why?
| | Fallopian Tubes | 1 | 2007 | 22 | 0.070 |
Why?
| | Genital Diseases, Female | 1 | 2007 | 17 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 578 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 118 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 1033 | 0.070 |
Why?
| | Risk Assessment | 1 | 2010 | 1270 | 0.060 |
Why?
| | Bacterial Proteins | 1 | 2009 | 367 | 0.060 |
Why?
| | Administration, Cutaneous | 1 | 2025 | 55 | 0.060 |
Why?
| | Food Handling | 1 | 2004 | 17 | 0.060 |
Why?
| | Receptors, Interferon | 1 | 2004 | 4 | 0.060 |
Why?
| | Homozygote | 1 | 2004 | 57 | 0.060 |
Why?
| | Sequence Deletion | 1 | 2004 | 67 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2018 | 2747 | 0.060 |
Why?
| | Gastrointestinal Diseases | 1 | 2005 | 125 | 0.060 |
Why?
| | Apoptosis | 1 | 2009 | 1097 | 0.050 |
Why?
| | Food Additives | 1 | 2002 | 7 | 0.050 |
Why?
| | Gelatin | 1 | 2002 | 23 | 0.050 |
Why?
| | Poverty | 1 | 2024 | 208 | 0.050 |
Why?
| | Pedigree | 1 | 2021 | 119 | 0.050 |
Why?
| | Cell Line | 3 | 2011 | 988 | 0.050 |
Why?
| | Comorbidity | 2 | 2015 | 623 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2015 | 1571 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 164 | 0.040 |
Why?
| | Infusions, Subcutaneous | 1 | 2020 | 2 | 0.040 |
Why?
| | Transdermal Patch | 1 | 2020 | 3 | 0.040 |
Why?
| | Cooking | 1 | 2020 | 18 | 0.040 |
Why?
| | Ovum | 1 | 2019 | 6 | 0.040 |
Why?
| | Powders | 1 | 2019 | 22 | 0.040 |
Why?
| | Diet Therapy | 1 | 2019 | 8 | 0.040 |
Why?
| | Immunity | 1 | 2019 | 34 | 0.040 |
Why?
| | Prospective Studies | 2 | 2017 | 2378 | 0.040 |
Why?
| | Tertiary Healthcare | 1 | 2019 | 15 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 106 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2021 | 640 | 0.040 |
Why?
| | Staff Development | 1 | 2018 | 22 | 0.040 |
Why?
| | Efficiency | 1 | 2018 | 32 | 0.040 |
Why?
| | Social Responsibility | 1 | 2018 | 25 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2018 | 34 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2018 | 79 | 0.040 |
Why?
| | Burnout, Professional | 1 | 2018 | 52 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 929 | 0.040 |
Why?
| | Transcriptome | 1 | 2019 | 314 | 0.040 |
Why?
| | Leadership | 1 | 2018 | 100 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 54 | 0.030 |
Why?
| | Seasons | 1 | 2017 | 79 | 0.030 |
Why?
| | Self Efficacy | 1 | 2018 | 130 | 0.030 |
Why?
| | Immunoblotting | 2 | 2009 | 115 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 829 | 0.030 |
Why?
| | Histamine Antagonists | 1 | 2016 | 19 | 0.030 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 83 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 349 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 372 | 0.030 |
Why?
| | Cell Line, Transformed | 2 | 2007 | 73 | 0.030 |
Why?
| | Communication | 1 | 2018 | 250 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 861 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 971 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2017 | 200 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 550 | 0.030 |
Why?
| | Cohort Studies | 1 | 2019 | 1452 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2015 | 22 | 0.030 |
Why?
| | Middle Aged | 2 | 2024 | 12614 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2017 | 734 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 1609 | 0.030 |
Why?
| | Emergency Treatment | 1 | 2013 | 30 | 0.030 |
Why?
| | Ofloxacin | 1 | 2013 | 7 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 573 | 0.030 |
Why?
| | Ceftriaxone | 1 | 2013 | 24 | 0.030 |
Why?
| | Plant Proteins | 1 | 2013 | 68 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2013 | 35 | 0.030 |
Why?
| | Doxycycline | 1 | 2013 | 32 | 0.030 |
Why?
| | Metronidazole | 1 | 2013 | 28 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 62 | 0.030 |
Why?
| | Amikacin | 1 | 2013 | 19 | 0.030 |
Why?
| | Glycoproteins | 1 | 2013 | 116 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2013 | 32 | 0.030 |
Why?
| | Azithromycin | 1 | 2013 | 25 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2013 | 36 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2013 | 63 | 0.030 |
Why?
| | Urticaria | 1 | 2013 | 18 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2012 | 7 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2012 | 12 | 0.030 |
Why?
| | Receptors, IgE | 1 | 2012 | 5 | 0.030 |
Why?
| | Eggs | 1 | 2012 | 8 | 0.030 |
Why?
| | Pyrophosphatases | 1 | 2012 | 13 | 0.030 |
Why?
| | Epitopes | 1 | 2012 | 59 | 0.030 |
Why?
| | Equipment Design | 1 | 2013 | 289 | 0.030 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2012 | 33 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 108 | 0.020 |
Why?
| | Hospitals, University | 1 | 2012 | 76 | 0.020 |
Why?
| | Patient Care Team | 1 | 2013 | 258 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 659 | 0.020 |
Why?
| | Tissue Donors | 1 | 2012 | 121 | 0.020 |
Why?
| | Trachoma | 1 | 2011 | 4 | 0.020 |
Why?
| | Guinea Pigs | 1 | 2011 | 75 | 0.020 |
Why?
| | Glycogen Synthase | 1 | 2011 | 1 | 0.020 |
Why?
| | Chromosomes, Bacterial | 1 | 2011 | 14 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 269 | 0.020 |
Why?
| | Inclusion Bodies | 1 | 2011 | 18 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 92 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2012 | 235 | 0.020 |
Why?
| | Genetic Loci | 1 | 2011 | 45 | 0.020 |
Why?
| | Glycogen | 1 | 2011 | 42 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 234 | 0.020 |
Why?
| | Pain | 1 | 2013 | 389 | 0.020 |
Why?
| | Clinical Competence | 1 | 2013 | 398 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 372 | 0.020 |
Why?
| | Drug Hypersensitivity | 1 | 2010 | 38 | 0.020 |
Why?
| | Virulence | 1 | 2011 | 168 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 468 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2011 | 216 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 2934 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 35 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 405 | 0.020 |
Why?
| | Diphenhydramine | 1 | 2009 | 19 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2009 | 70 | 0.020 |
Why?
| | Glucose | 1 | 2011 | 341 | 0.020 |
Why?
| | Albuterol | 1 | 2009 | 57 | 0.020 |
Why?
| | Gene Expression | 1 | 2011 | 610 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2009 | 76 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 340 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 85 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 25 | 0.020 |
Why?
| | Immunization, Secondary | 1 | 2007 | 21 | 0.020 |
Why?
| | Algorithms | 1 | 2010 | 628 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2007 | 105 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2011 | 1436 | 0.020 |
Why?
| | Mycobacterium avium Complex | 1 | 2004 | 5 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2004 | 19 | 0.010 |
Why?
| | Genes, Recessive | 1 | 2004 | 15 | 0.010 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2004 | 10 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 739 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2004 | 179 | 0.010 |
Why?
| | Transfection | 1 | 2004 | 356 | 0.010 |
Why?
| | Osteomyelitis | 1 | 2004 | 128 | 0.010 |
Why?
|
|
Scurlock's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|